Cellomics, Inc. Announces Appointment of Vice President, Operations.PITTSBURGH--(BW HealthWire)--Dec. 14, 1998--Cellomics, Inc. announced today the appointment of Alan W. Seadler, Ph.D., as Vice President of Operations. Dr. Seadler joins Cellomics from Visible Genetics, Inc., where he was Vice President of Reagent Production and Test Development with overall responsibility for starting and managing reagent production and a Pittsburgh-based R&D group. Dr. Seadler's prior experience includes senior management positions at Ciba-Corning, Fisher Scientific Fisher Scientific, formally Fisher Scientific International, Inc. and colloquially Fisher was a biotechnology company that provided products and services to the global scientific research and United States clinical laboratory markets. , Biological Detection Systems and Amersham Life Sciences. Dr. Seadler received his Ph.D. in Biology at Case Western Reserve University and completed his post-doctoral training at McGill University McGill University, at Montreal, Que., Canada; coeducational; chartered 1821, opened 1829. It was named for James McGill, who left a bequest to establish it. Its real development dates from 1855 when John W. Dawson became principal. . He taught at Case Western Reserve and John Carroll Universities prior to leaving the academic environment in 1977 to begin his career in biotechnology. "We are extremely happy to have Alan joining Cellomics' senior management team," stated D. Lansing Taylor, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Alan brings both start-up and large corporation experience to the Cellomics team. His experience will allow us to move even more quickly towards becoming a full service provider of platforms for High Content Screening, as well as informatics and screening kits for both High Throughput and High Content screening." Cellomics, Inc., is a privately held corporation Noun 1. privately held corporation - a corporation owned by a few people; shares have no public market close corporation, closed corporation, private corporation , founded in October 1996. Cellomics Inc.'s mission is to improve the efficiency of the drug discovery process by delivering a cell-based screening platform that automates target validation, primary screening and lead optimization using fluorescence-based assays. Today, the Company's integrated platform consists of proprietary fluorescence reagents and assays, a novel, proprietary, cell-based High Content Screening (HCS HCS - Heterogeneous Computer System A distributed system project. ) system, data management and bioinformatics software. Unlike traditional methods in the drug discovery process, the Company's platform provides deep biological information (time, space, and activity) about a drug candidate's physiological impact on specific cellular targets within living cells. This approach provides significant insight into the potential efficacy and toxicity of a drug candidate on cells before initiating animal testing Animal testing or animal research refers to the use of animals in experiments. It is estimated that 50 to 100 million vertebrate animals worldwide [4][5][6] and human clinical trials, thereby saving substantial time and expense. In addition, the Company co-markets the Carl Zeiss Ultra High Throughput Screening (UHTS UHTS Ultrahigh-Throughput Screening (Pharmaceutical Industry) UHTS Universal Hydraulic Test Stand ) system that can be combined directly with the Cellomics, Inc. HCS system through an exclusive, world-wide alliance with Carl Zeiss Jena, GmbH, the world's leader in optical instrumentation and automation. Cellomics, Inc. will develop new reagents, complete screens, data management tools and bioinformatics as part of the alliance. Combining UHTS with HCS is a new paradigm New Paradigm In the investing world, a totally new way of doing things that has a huge effect on business. Notes: The word "paradigm" is defined as a pattern or model, and it has been used in science to refer to a theoretical framework. in drug discovery. The Company is also developing the next generation, cell-based screening platform, the CellChip(TM) System, and the Cellomics(TM) Database to further optimize the drug discovery process. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion